GETI.B

195.2

+0.46%↑

ATT

102.8

-0.39%↓

AMBEA

135.1

+0.6%↑

ARJOB

26.24

+1.55%↑

MSON.B

10.7

-0.93%↓

GETI.B

195.2

+0.46%↑

ATT

102.8

-0.39%↓

AMBEA

135.1

+0.6%↑

ARJOB

26.24

+1.55%↑

MSON.B

10.7

-0.93%↓

GETI.B

195.2

+0.46%↑

ATT

102.8

-0.39%↓

AMBEA

135.1

+0.6%↑

ARJOB

26.24

+1.55%↑

MSON.B

10.7

-0.93%↓

GETI.B

195.2

+0.46%↑

ATT

102.8

-0.39%↓

AMBEA

135.1

+0.6%↑

ARJOB

26.24

+1.55%↑

MSON.B

10.7

-0.93%↓

GETI.B

195.2

+0.46%↑

ATT

102.8

-0.39%↓

AMBEA

135.1

+0.6%↑

ARJOB

26.24

+1.55%↑

MSON.B

10.7

-0.93%↓

Inicio・Lista de Acciones・Vivesto AB

Vivesto AB

Cerrado

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Métricas clave
By Trading Economics
Ingresos	-1.9M -9.1M
BPA	-0.013
Empleados	4
EBITDA	-1.8M -8.9M

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-124K 51M
Apertura anterior	0
Cierre anterior	0

Vivesto AB Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 mar 2026, 20:38 UTC

Ganancias

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mar 2026, 23:57 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

10 mar 2026, 23:57 UTC

Charlas de Mercado

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mar 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mar 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mar 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mar 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mar 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mar 2026, 23:35 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mar 2026, 23:06 UTC

Ganancias

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mar 2026, 22:51 UTC

Noticias de Eventos Importantes

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mar 2026, 21:39 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mar 2026, 21:21 UTC

Ganancias

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mar 2026, 21:15 UTC

Ganancias

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mar 2026, 21:15 UTC

Adquisiciones, fusiones, absorciones

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mar 2026, 21:14 UTC

Ganancias

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mar 2026, 21:13 UTC

Ganancias

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mar 2026, 21:12 UTC

Ganancias

Franco-Nevada 4Q Rev $597.3M >FNV

10 mar 2026, 21:12 UTC

Ganancias

Franco-Nevada 4Q EPS $1.90

10 mar 2026, 20:57 UTC

Ganancias

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

10 mar 2026, 20:44 UTC

Ganancias

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:34 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

10 mar 2026, 20:34 UTC

Charlas de Mercado

Ganancias

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mar 2026, 20:23 UTC

Ganancias

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:16 UTC

Ganancias

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mar 2026, 20:14 UTC

Ganancias

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mar 2026, 20:14 UTC

Ganancias

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mar 2026, 20:13 UTC

Ganancias

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mar 2026, 20:12 UTC

Ganancias

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Comparación entre iguales

Cambio de precio

Vivesto AB previsión

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.